A War on Two Fronts

Hey Influence Traders,


I’m still soaking up the sun in Europe.


Andrew Giovinnazi has been manhandling the Capitol Gains portfolio in my absence.


I wanted to give some quick thoughts on the goings-on in DC, and talk about a stock I’m eyeing in light of the FDA’s full approval of the Pfizer (Ticker: PFE) vaccine.


Politics


Like her or hate her, Nancy Pelosi showed her political clout this week when she rallied her base to pass a party line vote to start working on a $3.5 trillion Dem “wish list” bill.


But she’s fighting a war on two fronts.


Or perhaps three fronts.


She’s got the Republicans firmly against her plans for the $3.5 trillion boondoggle.


Moderate Democrats are supporting her, provided she holds an immediate vote on the $1.2 trillion infrastructure bill.


But House Progressives only care about the $3.5 trillion bill, which prioritizes more ‘social’ issues, and some are threatening to vote against the infrastructure bill if it comes to the floor before the $3.5 trillion bill.


So far, Pelosi has formed a tight alliance with Rep. Pramila Jayapal, the Congressional Progressive Caucus leader, which might spell bad news for moderates.


I’ve got my popcorn and a Negroni and am watching the show!


CVS


In addition to helping Pfizer, the recent FDA grant of full approval will cause jabs to increase.


Healthcare is shifting in the US, with much frontline preventive care shifting to a European model of being dispensed through pharmacies.


CVS Health Corp (Ticker: CVS) is on my radar screen for several reasons. For one CVS is a vaccination leader. It’s also closing non-productive stores, and shifting some retail space to medical clinic space.


Cutting through the noise for you,


Frank

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.